BioCity Biopharma

Focus: BioCity Biopharma is a China-based biopharmaceutical company founded in 2022 focused on small molecules and antibodies across oncology, nephrology, metabolic diseases, and neurology. The company operates as a pre-revenue biotech with an early-stage pipeline in clinical development.

Oncology Nephrology Metabolic Diseases Neurology

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Open Jobs

About BioCity Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow BioCity Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BC3402 Injection

Hematologic Malignancy

PHASE_1

Clinical Trials (1)

NCT05690425A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML

Phase 1

Help build intelligence for BioCity Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to join a newly founded (2022) organization with greenfield potential in high-value therapeutic areas including oncology and rare kidney diseases
Exposure to 11 active clinical programs with lead asset SC0062 in Phase 3 for IgA Nephropathy, offering near-term catalysts
Small team structure (hiring actively in HR) enables rapid individual impact and broad cross-functional visibility in early-stage development

Watch Out For

Extreme early-stage risk: company is pre-revenue with no marketed products, dependent entirely on pipeline success and continued funding
Minimal hiring activity (only 1 open role in HR) and undisclosed financial details create uncertainty about company stability, growth trajectory, and compensation competitiveness
Limited transparency on headcount, funding status, and financial position makes it difficult to assess long-term viability or career growth infrastructure

Generated by Claude from BioCity Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Drug: BC3195 for Injection

Locally Advanced or Metastatic Solid Tumors

PHASE_1

Clinical Trials (1)

NCT05957471Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors

Phase 1

BC2027 for Injection

Advanced Solid Malignancies

PHASE_1

Clinical Trials (1)

NCT07368478A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Phase 1

BC3402

Myelodysplastic Syndromes

PHASE_1

Clinical Trials (1)

NCT05970822Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Phase 1

BC3195

Advanced Cancer

PHASE_1

Clinical Trials (1)

NCT06548672A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer